Study Finds Cannabis Components CBG And THCV Promising Treatments for Parkinson’s And Alzheimer’s

Marijuana Components CBG And THCV Are ‘Promising’ Treatments For Parkinson’s And Alzheimer’s per studyPhoto byThought CatalogonUnsplash

A new study released shows the therapeutic potential of Cannabis sativa extends well beyond the widely studied CBD, encompassing a diverse range of lesser‐known phytocannabinoids that show promise in addressing various neurological disorders. The neuroprotective functions of these NMPs, particularly their antioxidant, anti‐inflammatory, and immune‐modulating properties, offer new avenues for research and treatment. While the pharmacological mechanisms of many NMPs remain underexplored, emerging studies suggest their potential to develop novel therapies for brain disorders. As research continues to unfold, these findings could pave the way for innovative cannabinoid plant‐based treatments that go beyond the scope of traditional approaches, offering newhope in neuroprotection and disease management.

This new scientific review on the potential benefits of marijuana in treating brain disorders says that in addition to THC and CBD produced by the cannabis plant, “a diverse array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids” may also “demonstrate diverse pharmacological activities” and could offer therapeutic applications. Such compounds include THCV, CBDV and CBG.

Their antioxidant, anti-inflammatory and neuromodulatory effects position them as promising agents in treating neurodegenerative disorders,” says the report, authored by a pair of researchers from the Center for Dementia Research at the Nathan Kline Institute for Psychiatric Research in New York and released last month.

Authors evaluated available scientific literature about minor cannabinoids and conditions such as epilepsy, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and substance and alcohol use disorders. They found evidence not only of neuroprotective effects but also other beneficial outcomes.

“The therapeutic potential of Cannabis sativa extends well beyond the widely studied CBD,” the report says, “encompassing a diverse range of lesser‐known phytocannabinoids that show promise in addressing various neurological disorders.”

Similar phenomena are also beginning to be recorded around psychedelic plants and fungi. In March, for example, researchers published findings showing that use of full-spectrum psychedelic mushroom extract had a more powerful effect than chemically synthesized psilocybin alone. They said the findings imply that mushrooms, like cannabis, demonstrate an entourage effect.

The CDR has become an internationally recognized research center, attracting outstanding personnel, and bringing millions of federal dollars annually to New York to help support its mission. The Center for Dementia Research (CDR) at NKI is a consortium of independent laboratories and research programs, directed by Dr. Ralph A. Nixon, dedicated to studies on the pathogenesis, diagnosis, and treatment of AD and other major neurodegenerative diseases.

Link to Study